Ratings ArcticZymes Technologies ASA

Equities

AZT

NO0010014632

Market Closed - Oslo Bors Other stock markets 08:15:00 14/05/2024 pm IST			5-day change	1st Jan Change
23 ^NOK	+2.22%		-8.91%	-45.24%

13/05	ArcticZymes Technologies ASA Announces Board Resignations	CI
08/05	ArcticZymes Technologies ASA Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The company returns high margins, thereby supporting business profitability.
Thanks to a sound financial situation, the firm has significant leeway for investment.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 52.39 times its estimated earnings per share for the ongoing year.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company appears highly valued given the size of its balance sheet.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ARCTICZYMES TECHNOLOGIES ASA	-45.24%	106M	-
MODERNA, INC.	+29.03%	48.16B	B-
IQVIA HOLDINGS INC.	-0.10%	41.73B	B
LONZA GROUP AG	+43.45%	41.03B	A
CELLTRION, INC.	-5.26%	28.77B	C
ICON PUBLIC LIMITED COMPANY	+11.48%	25.59B	B-
ALNYLAM PHARMACEUTICALS, INC.	-22.74%	18.96B	B
BIO-TECHNE CORPORATION	+9.06%	12.92B	B+
MEDPACE HOLDINGS, INC.	+30.01%	12.03B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.51%	11.77B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes